Esperion Therapeutics (NASDAQ:ESPR) Shares Up 3.3%
Esperion Therapeutics (NASDAQ:ESPR) Shares Up 3.3%
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) shot up 3.3% during trading on Tuesday . The stock traded as high as $6.91 and last traded at $6.91. 115,696 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,422,240 shares. The stock had previously closed at $6.69.
Esperion Treateutics，Inc.(納斯達克代碼：ESPR-GET評級)的股價在週二的交易中飆升了3.3%。該股最高交易價格為6.91美元，最後報6.91美元。午盤成交量為115,696股，較1,422,240股的平均成交量下降92%。該股此前收盤價為6.69美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several brokerages have commented on ESPR. Morgan Stanley raised their price target on shares of Esperion Therapeutics from $7.00 to $9.00 and gave the company an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com raised shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $11.20.
幾家券商對ESPR發表了評論。11月2日，週三，摩根士丹利在一份研究報告中將Esperion治療公司的股票目標價從7.00美元上調至9.00美元，並給予該公司“減持”評級。在11月3日星期四的一份研究報告中，StockNews.com將Esperion治療公司的股票評級從“賣出”上調至“持有”。兩名股票研究分析師對該股的評級為賣出，兩名分析師給予該股持有評級，一名分析師對該股給予買入評級。根據MarketBeat.com的數據，該股目前的平均評級為持有，共識目標價為11.20美元。
Esperion Therapeutics Stock Performance
Esperion Treateutics股票表現
The company's 50 day moving average is $6.54 and its 200 day moving average is $6.98.
該公司的50日移動均線切入位在6.54美元，200日移動均線切入位在6.98美元。
Insider Buying and Selling at Esperion Therapeutics
Esperion Treateutics的內幕買賣
In other Esperion Therapeutics news, General Counsel Benjamin Looker sold 6,347 shares of Esperion Therapeutics stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $7.00, for a total value of $44,429.00. Following the transaction, the general counsel now directly owns 64,453 shares in the company, valued at $451,171. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 3.30% of the stock is currently owned by company insiders.
在其他Esperion治療公司的消息中，總法律顧問Benjamin Looker在1月18日星期三的一筆交易中出售了6,347股Esperion治療公司的股票。這些股票的平均價格為7.00美元，總價值為44429.00美元。交易完成後，總法律顧問現在直接擁有該公司64,453股，價值451,171美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在以下網址獲得美國證券交易委員會網站。3.30%的股份目前由公司內部人士持有。
Institutional Trading of Esperion Therapeutics
Esperion治療藥物的制度性交易
A number of institutional investors have recently added to or reduced their stakes in the stock. Wasatch Advisors Inc. boosted its holdings in Esperion Therapeutics by 27.6% during the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock worth $37,804,000 after buying an additional 1,761,117 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Esperion Therapeutics by 19.4% during the first quarter. Vanguard Group Inc. now owns 4,491,530 shares of the biopharmaceutical company's stock worth $20,841,000 after buying an additional 730,091 shares in the last quarter. Millennium Management LLC boosted its holdings in Esperion Therapeutics by 116.8% during the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock worth $17,212,000 after buying an additional 1,457,952 shares in the last quarter. Ikarian Capital LLC purchased a new stake in Esperion Therapeutics during the second quarter worth about $13,067,000. Finally, State Street Corp boosted its holdings in Esperion Therapeutics by 23.2% during the third quarter. State Street Corp now owns 1,533,148 shares of the biopharmaceutical company's stock worth $10,272,000 after buying an additional 288,609 shares in the last quarter. Hedge funds and other institutional investors own 85.87% of the company's stock.
一些機構投資者最近增持或減持了該股。Wasatch Advisors Inc.在第一季度將其在Esperion Treateutics的持股增加了27.6%。Wasatch Advisors Inc.現在持有這家生物製藥公司8,147,380股票，價值37,804,000美元，上個季度又購買了1,761,117股票。先鋒集團第一季度增持了Esperion Treateutics 19.4%的股份。先鋒集團(Vanguard Group Inc.)現在持有這家生物製藥公司4,491,530股股票，價值20,841,000美元，上季度又購買了730,091股。千禧管理有限責任公司在第二季度增持了116.8%的Esperion Treateutics股份。Millennium Management LLC現在擁有這家生物製藥公司2,706,290股股票，價值17,211,000美元，上個季度又購買了1,457,952股。伊卡里安資本有限責任公司在第二季度購買了Esperion治療公司的新股份，價值約13,067,000美元。最後，道富銀行在第三季度增持了Esperion治療公司23.2%的股份。道富集團目前持有這家生物製藥公司1,533,148股股票，價值10,272,000美元，上一季度又購買了288,609股。對衝基金和其他機構投資者持有該公司85.87%的股票。
Esperion Therapeutics Company Profile
Esperion治療公司簡介
(Get Rating)
(獲取評級)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Esperion Treateutics，Inc.是一家制藥公司，開發和銷售治療低密度脂蛋白膽固醇升高患者的藥物。它的主要候選產品是用於治療動脈粥樣硬化性心血管疾病或雜合性家族性高膽固醇血癥患者的NEXLETOL(苯培多酸)和NEXLIZET(苯培多酸和依折麥布)片劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
- 免費獲取StockNews.com關於Esperion治療(ESPR)的研究報告
- Intuit即將採取行動，但走哪條路呢？
- 1月下旬收益表現出流行音樂的潛力
- 低價股仍在派發股息
- 為什麼Chipotle的股價本週飆升？
- 諾斯羅普·格魯曼公司的拋售是一個機會嗎？
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Esperion治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Esperion Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。